QED Clinical Services, a customer focused, full service, global clinical research organization (CRO), has announced the creation of a wholly owned subsidiary “QED Clinical Services India Prviate Limited” in Ahmedabad, India, to enhance its global delivery of clinical trials. These developments further strengthen QED’s position as one of the most innovative and advanced companies in clinical development, adding operational and therapeutic expertise. The creation of the Indian subsidiary also expands QED’s capacity and capabilities to offer more global coverage to continue to successfully deliver high quality, cost effective projects.
QED operations in India will be spearheaded by Country Head and Director of Operations, Ali Saijad Bohra. Ali brings extensive leadership experience in Clinical Monitoring, Functional Services (FSP models) and Project Management across major Asia Pacific markets i.e. India, South East Asia countries, Japan, S.Korea and Australia. Ali has also previously served as Asia Pacific Regional Director for Clinical Monitoring group of a large global CRO.
Ali commented that “India and the Asia Pacific region will continue to have focus and will remain key markets for the drug development activities for biopharmaceutical companies on account of a variety of benefits. With our in-depth experience and knowledge of the region, we are committed to provide customised, cost-efficient and high quality services both global as well as local clients”.
In addition to the conduct of trials in India, QED Clinical, India will act as a hub for QED’s Asia Pacific operations to enhance control and oversight of its local partners across the wider Asia Pacific region.
Thomas Ogorka, CEO, said “The creation of QED Clinical, India means that we can better meet the global development needs of our sponsors by giving access to vast patient populations via regional experts on the ground. India continues to receive great focus as an emerging territory and QED’s presence here means we can leverage its high-quality capabilities”.